Title : ( Enhanced anticancer efficacy of epirubicin-loaded mesoporous silica nanocarriers through co-delivery of an antimiR-21 expressing plasmid to target colon adenocarcinoma in vitro and in vivo )
Authors: Amir Abrishami , Ahmad Reza Bahrami , Amir SHokooh Saljooghi , Maryam Moghaddam Matin ,
Full TextAbstract
Introduction: Cancer chemotherapy faces two main limitations including severe side effects and drug resistance. Novel methods in targeted drug delivery have established biocompatible nanocarriers, which can increase the efficacy of chemotherapy in combination with gene therapy, while reducing the side effects. Since overexpression of miR-21 and its association with epirubicin(EPI)-induced resistance is involved in colorectal cancer (CRC) progression, using efficient targeted nanocarriers to overcome drug resistance by miR-21 inhibition seems a promising approach. Methods: In this study, we first designed and synthesized mesoporous silica nanoparticles (MSNs) as the backbone of the drug delivery system (DDS). After equipping MSNs with EPI as anticancer drug and antimiR-21 expressing plasmid, the DDS was PEGylated and armed with AS1411 aptamer for active targeting of CRC cells. The prepared nanocarriers were fully characterized in terms of size and morphological properties as well as elemental composition. Encapsulation and release of EPI and pDNA were investigated by spectrophotometry and gel electrophoresis, respectively. To estimate PEGylation influence on biocompatibility improvement, hemolysis assay was performed. Afterwards, anticancer synergistic effects were investigated with MTT assay and apoptosis measurement. Moreover, cellular uptake and transfection efficacy were compared in C26 colorectal cancer cells and NIH/3T3 as a normal cell line. Results: Successful production of the DDS with a mean diameter less than 70 nm was demonstrated by physicochemical characterization results; and loading content (LC) of EPI and pDNA was indicated as 25 and 10%, respectively. Hemolysis results confirmed the biocompatibility of nanocarriers, and the synergistic cytotoxicity and uptake of targeted formulation was significantly higher in C26 cells compared to nucleolin negative NIH/3T3 cells. Conclusion: According to the results, the targeted biocompatible DDS combining chemo and gene therapy could strongly enhance the anticancer properties of epirubicin, while reducing its side effects.
Keywords
, Colorectal cancer, Targeted therapy, Gene therapy, Epirubicin, miR-21
@inproceedings{paperid:1095287,
author = {Abrishami, Amir and Bahrami, Ahmad Reza and SHokooh Saljooghi, Amir and Moghaddam Matin, Maryam},
title = {Enhanced anticancer efficacy of epirubicin-loaded mesoporous silica nanocarriers through co-delivery of an antimiR-21 expressing plasmid to target colon adenocarcinoma in vitro and in vivo},
booktitle = {The First International Congress of Cancer Genomics (CGC2023)},
year = {2023},
location = {تهران, IRAN},
keywords = {Colorectal cancer; Targeted therapy; Gene therapy; Epirubicin; miR-21},
}
%0 Conference Proceedings
%T Enhanced anticancer efficacy of epirubicin-loaded mesoporous silica nanocarriers through co-delivery of an antimiR-21 expressing plasmid to target colon adenocarcinoma in vitro and in vivo
%A Abrishami, Amir
%A Bahrami, Ahmad Reza
%A SHokooh Saljooghi, Amir
%A Moghaddam Matin, Maryam
%J The First International Congress of Cancer Genomics (CGC2023)
%D 2023
